Your browser doesn't support javascript.
loading
Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.
Nambulli, Sham; Xiang, Yufei; Tilston-Lunel, Natasha L; Rennick, Linda J; Sang, Zhe; Klimstra, William B; Reed, Douglas S; Crossland, Nicholas A; Shi, Yi; Duprex, W Paul.
Afiliación
  • Nambulli S; Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
  • Xiang Y; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
  • Tilston-Lunel NL; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Rennick LJ; Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
  • Sang Z; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
  • Klimstra WB; Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
  • Reed DS; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
  • Crossland NA; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Shi Y; University of Pittsburgh-Carnegie Mellon University Program in Computational Biology, Pittsburgh, PA, USA.
  • Duprex WP; Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
Sci Adv ; 7(22)2021 05.
Article en En | MEDLINE | ID: mdl-34039613
Globally, there is an urgency to develop effective, low-cost therapeutic interventions for coronavirus disease 2019 (COVID-19). We previously generated the stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21). Using Syrian hamsters that model moderate to severe COVID-19 disease, we demonstrate the high efficacy of PiN-21 to prevent and treat SARS-CoV-2 infection. Intranasal delivery of PiN-21 at 0.6 mg/kg protects infected animals from weight loss and substantially reduces viral burdens in both lower and upper airways compared to control. Aerosol delivery of PiN-21 facilitates deposition throughout the respiratory tract and dose minimization to 0.2 mg/kg. Inhalation treatment quickly reverses animals' weight loss after infection, decreases lung viral titers by 6 logs leading to drastically mitigated lung pathology, and prevents viral pneumonia. Combined with the marked stability and low production cost, this innovative therapy may provide a convenient and cost-effective option to mitigate the ongoing pandemic.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos de Dominio Único / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Límite: Animals Idioma: En Revista: Sci Adv Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos de Dominio Único / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Límite: Animals Idioma: En Revista: Sci Adv Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos